| II-019 Ikhlas Guermi Development of a pharmacokinetic-pharmacodynamic model to describe blood hepcidin levels in patients with myelofibrosis and assess target engagement of zilurgisertib, an ALK2 inhibitor Wednesday 15:20-16:50 |
| II-019 Ikhlas Guermi Development of a pharmacokinetic-pharmacodynamic model to describe blood hepcidin levels in patients with myelofibrosis and assess target engagement of zilurgisertib, an ALK2 inhibitor Wednesday 15:20-16:50 |